Allie LogoA Search Service for Abbreviation / Long Form

■略語／展開語 : EVO／evolocumab

関連PubMed/MEDLINE情報

合計出現文献数:

5

略語:

EVO

(

>>共起略語

)

展開形:

evolocumab

(ヒト型抗PCSK9抗体;LDLコレステロール低下) エボロクマブ

EVO (5)回

evolocumab (5)回

EVO / evolocumab (5)回

No.
発表年
題目
共起略語

1

2025

Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China.
ASCVD, CNY, ICERs, INC, NDPN, PCSK9, QALY, SOC

2

2023

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Podocytes in Mouse Nephrotic Syndrome.
ADR, NLRP3, NS, PCSK9, ox-LDL

3

2017

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
ALI, ALI-EVO, CVD, HeFH, LDL-C, PCSK9

4

2017

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.
ALI, CVD, HeFH, LDL-C, PCSK9

5

2017

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
ALI, CVD, FDA, LDL-C, LLT, MTD, MTDLLT

Rows per page:

1–5 of 5